Articles tagged with Drug Therapy
Researchers found that pacing patients at faster heart rates improved quality of life, physical activity, and reduced atrial fibrillation. This new treatment approach shows promise in treating heart failure with a stiff heart muscle.
A genomic study of the Seattle 2017-2022 Shigella outbreak revealed its origin as international travelers from areas where Shigella was common. The study also found that multi-drug resistant Shigella has become a growing global health concern, primarily affecting men who have sex with men and those experiencing homelessness.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
Researchers from TIBI have developed an advanced electronic skin patch that provides simultaneous, continuous monitoring of multiple bodily parameters. The new E-skin patch offers enhanced flexibility, thermal cooling abilities, and fluid absorption over conventional substrates while demonstrating excellent biocompatibility and biodegr...
A novel form of chemoimmunotherapy has been proven to be a promising treatment for canine cancer, extending the lives of terminally ill dogs. The therapy uses modified Mesenchymal Stem Cells carrying a potent 'kill-switch' that induces anti-cancer immunity and improves quality of life.
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.
Regulatory T cells suppress self-reactive T cells by controlling protein synthesis, maintaining immune tolerance and preventing autoimmunity. A small molecule inhibitor called RocA also shows promise in mitigating inflammatory responses.
Researchers found that patients used various therapeutic strategies to alleviate symptoms, including mind-body medicine, nutritional supplements, exercise, and olfactory training. Many patients need more understanding, recognition, and specific post-COVID health care services, as well as empathy from their doctors.
A controlled clinical trial has shown that the new drug leriglitazone can prevent neurodegeneration and brain inflammation in patients with X-linked adrenoleukodystrophy. The study found improvements in neurological conditions such as balance disorders, which had a positive impact on quality of life.
Researchers have identified the genetic secrets behind skullcap's anti-cancer activity, enabling the production of synthetic compounds. The discovery is expected to lead to more sustainable and rapid synthesis of cancer-fighting molecules.
Researchers successfully applied AlphaFold AI to an end-to-end platform, discovering a novel target and developing a potent hit molecule for liver cancer. The study demonstrates the potential of AI-powered drug discovery to accelerate treatment development.
A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.
A new personalized treatment for bile duct cancer has shown remarkable results, with patients surviving for up to two years when treated with the drug futibatinib. The Phase II clinical trial found that the drug was more effective at reducing tumor size and producing modest side effects compared to chemotherapy.
A recent study from West Virginia University found that states permitting nurse practitioners to exercise full practice authority (FPA) tend to have a more diverse and racially aligned NP workforce. In FPA states, Black NPs serve 2.8% more Black Medicare beneficiaries than in non-FPA states.
A large cohort study found that long-term low-dose hydroxychloroquine use is associated with a low risk of developing retinopathy, while higher doses increase the risk. Regular screening can identify the issue at an early stage.
Fewer than one-third of commonly advertised drugs show moderate clinical improvement compared to existing therapies. The study analyzed direct-to-consumer TV advertising and found most featured drugs to lack substantial therapeutic benefits.
A study of 4,768 patients with cancer found that SARS-CoV-2 infection led to delayed or discontinued cancer treatment, exacerbating existing survival inequities. Racial and area-level social determinants were associated with these delays.
A study shows that pharmacies can offer a safe starting point for patients with opioid use disorder, leading to higher rates of retention in treatment. The pharmacy-based model increases access to buprenorphine, a lifesaving medication, for diverse patient populations and promotes racial and economic equity.
A study from Japan found that variations in psychiatric diagnoses across different cultures can affect the efficacy of antipsychotics in clinical trials. Researchers analyzed data from 28 double-blind randomized trials and found that psychotic features were associated with varying therapeutic responses to antipsychotic medications.
Researchers have discovered a new biomarker that predicts the response to CAR-T cell therapy in patients with diffuse large B cell lymphoma. The biomarker identifies differentiated T cells, which can be removed from leukemia products to improve therapy success rates.
Researchers at UBC identified three compounds derived from natural sources that prevent COVID-19 infection in human cells. The discovery paves the way for developing new medicines using natural sources.
A new genetic test has been developed to identify ovarian cancer patients who benefit from PARP inhibitors, a treatment option with significant improvements in prognosis. The test has been optimized for the Finnish population and is clinically approved, allowing for targeted treatment and reduced adverse effects.
A nationwide registry of AVM patients from 52 hospitals in mainland China investigated the efficacy of different treatments on patient groups. The study found that categorizing treatment strategies based on disease severity is an ideal approach, and a multidisciplinary comprehensive assessment promotes individualized treatment protocols.
Researchers from prominent institutions discuss hepatocellular carcinoma's pathogenesis, genomic heterogeneity, and targeted therapy options. The review aims to characterize HCC's complexities and develop clinically relevant biomarkers for better management.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers developed a cell-based method to predict breast cancer treatment responses, showing promising results and potential for personalized medicine. The method uses tumour cells and supporting cells from patients, allowing for efficient drug profiling and accurate treatment prediction.
Extracellular vesicles from immune cells have been shown to activate the immune system in mice with skin cancer, rendering them sensitive to checkpoint inhibitor therapy. The treatment improved survival rates when used in combination with checkpoint inhibitors.
Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.
Dupilumab, an FDA-approved medication, offers new hope for patients with eosinophilic esophagitis, a rising condition in the US. The treatment reduces eosinophil counts and improves symptoms of dysphagia, leading to better endoscopic healing and histologic severity improvements.
The use of 3D-patient tumor avatars (3D-PTAs) is crucial for guiding treatment decisions in precision oncology. These avatars, including patient-derived organoids, 3D bioprinting, and microscale models, can accurately depict a tumor with its microenvironment, enabling the testing and prediction of therapeutic drug efficacy.
A study found that Medicare costs for metastatic prostate cancer increased significantly between 2007 and 2017, with average annual spending per patient rising from $28,311 to $37,055. The majority of the increase was attributed to new treatments under Medicare Part D, such as radium-223, sipuleucel-T, abiraterone, and enzalutamide.
Researchers from Complexity Science Hub and Medical University of Vienna found that high doses of cholesterol-lowering statins impair bone quality in mice, with a significant increase in osteoporosis risk. The study confirms previous findings on the correlation between statin use and osteoporosis diagnosis in humans.
Researchers at HKUMed identified a new type of nasopharyngeal carcinoma associated with EBV and immunosuppression in the tumor microenvironment. Global DNA hypermethylation was found to be a critical step in NPC pathogenesis, while global DNA hypomethylation may lead to immune evasion.
A large VA clinical trial found that chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for preventing cardiovascular disease or non-cancer death. The study enrolled over 13,500 Veterans with high blood pressure and showed no difference between the two drugs in terms of effectiveness.
A recent study suggests that stimulating the intersection of two particular brain networks correlated with better patient outcomes than stimulating nearby sites for patients with Alzheimer's disease. Cognitive improvement was associated with DBS to the direct interface between the fornix and bed nucleus of the stria terminalis.
Researchers describe results using cladribine-based combination epigenetic and immunotherapy in MCL, achieving an increased overall survival greater than 40 months with durable remissions without relapse for longer than 5 years. The approach is promising in the treatment of MCL and potentially other previously treatment-refractory canc...
Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.
A team of researchers at Tokyo Medical and Dental University has designed and synthesized novel compounds that have the potential to be effective drugs against COVID-19. The compounds target the main protease enzyme of the SARS-CoV-2 virus, which is essential for viral replication.
Researchers found that activating the non-mutated form of P53 can change the fundamental makeup of cancer stem cells in mouse models of mucoepidermoid carcinoma. This new therapy approach shows promise for treating this lethal form of salivary gland cancer.
The SERENA-2 trial found camizestrant significantly improves progression-free survival versus fulvestrant in patients with estrogen receptor-positive, HER2-negative breast cancer. Camizestrant demonstrates efficacy across various patient populations, including those with ESR1 mutations and prior CDK4/6 inhibitor treatment.
A UCLA-developed wearable patch analyzes fluid underneath the skin to continuously record medicine concentrations in the body. The technology shows reliable forecasts of total effective medication delivery, offering a step toward improving doctors' ability to administer precise doses.
The study suggests a significant decrease in US melanoma mortality rates, thanks to the availability of effective therapies and new pharmacological treatments. These findings are encouraging and support the continued development of such therapies.
Treatment with acetylcholinesterase inhibitors, with or without memantine, may reduce mortality risk and length of stay for unplanned hospital admissions among individuals with dementia with Lewy bodies. The study analyzed data from the UK to support this association.
A new study found that obeticholic acid can reverse cognitive impairment in patients with cholestatic liver disease, improving short-term memory and restoring brain function. The study used a rodent model of bile duct ligation-induced cholestasis and found that the drug significantly improved cognitive deficits.
A new antimalarial drug, tafenoquine, is found to require a higher dose of 450mg to achieve cure rates of 85% compared to the current 300mg dose of 70%. The study suggests that the single-dose tafenoquine is not as effective as optimal primaquine treatment in preventing vivax malaria relapses in all endemic regions.
The NSF is funding projects that utilize the International Space Station (ISS) National Laboratory to advance tissue engineering and mechanobiology research. This solicitation aims to further drug discovery and therapeutic development through space-based research, with potential impacts on regenerative medicine and disease diagnosis.
Rice University researchers are developing implants that can produce and deliver monoclonal anti-HIV antibody therapeutics for at least a year. The project aims to reduce the cost and improve the logistics of HIV treatment, making it more accessible and beneficial for patients worldwide.
Researchers discover how E. coli bacteria manipulate the immune system to cause ileocolitis in susceptible individuals. The study reveals the key role of agr2-associated ER stress in promoting dysbiosis and triggering CD103+ dendritic cell IL-23-dependent inflammation.
Researchers found that glutaminase inhibitor BPTES selectively eliminates senescent dermal fibroblasts, improving skin aging phenotype by increasing collagen density and cell proliferation. The study suggests BPTES as a potential therapeutic agent for skin aging, offering new treatment options.
Researchers found that dimethyl fumarate treatment increased the proportion of beneficial gut bacteria and reduced pro-inflammatory types, which are associated with MS. The study suggests a potential connection between gut flora and clinical side effects, paving the way for personalized treatment approaches.
The Phase II/III study found that acoziborole has an 18-month treatment success rate of 95% for late-stage patients and 100% for early-stage patients, with no significant safety concerns reported. This breakthrough could lead to the elimination of sleeping sickness through a simplified 'screen-and-treat' approach.
A new national study found pregnant women in legalized US states are far more likely to use cannabis, with a 4.6 times higher rate compared to CBD-only states. The study emphasizes the need for prenatal and primary care providers to screen and counsel patients regarding cannabis use in pregnancy.
Researchers found that prednisolone has no effect on improving sense of smell after COVID-19, but patients' sense of smell gradually improves over time. The study suggests that corticosteroids may not be an effective treatment option for persistent olfactory disorders after COVID-19.
Researchers at the University of Houston have developed a protocol to reprogram human heart cells into specialized cells that conduct electricity, enabling rhythmic heartbeat and repair diseased hearts. The discovery could lead to improved cardiac function and new pharmacological therapies for heart diseases.
A Michigan Medicine-led study reveals that transgender youth are 5.4 times more likely to experience insomnia and three times more likely to suffer from sleep apnea compared to cisgender youth. Gender-affirming therapies may offer a protective effect against worsening sleep health, according to the researchers.
Researchers are exploring how aging affects communication between bone and muscle, finding that imbalance can lead to muscle loss, falls, and bone fractures. They aim to develop novel interventions to restore this balance, potentially treating osteoporosis and sarcopenia.
Researchers have discovered how a new class of drugs can inhibit the complement system, which causes damage to the body in some cases. These findings pave the way for further optimization of such inhibitors, potentially leading to novel therapeutic strategies for treating autoimmune diseases.
A large registry-based study found lisdexamfetamine to be associated with the lowest risk of hospitalisation and death in people with amphetamine addiction. The medication showed a significant reduction in hospitalisation due to substance use disorder and any cause or death, while benzodiazepine and antidepressant use were linked to po...
A novel HNF1A gene variant has been found to cause monogenic diabetes, affecting almost seven percent of all cases in Greenland. This discovery may pave the way for precision treatment using tablet therapy with sulphonylurea, offering a simpler and cheaper alternative to insulin.
A three-year research project led by Aston University aims to prevent epileptic seizures in children. The team will explore how epilepsy becomes established in the brain and test new drugs using living tissue samples.